Noropin is developed by The Hawkins Foundation.

What development phase is Noropin in?

Noropin is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Noropin

The Hawkins Foundation · FDA-approved active Small molecule Quality 0/100

At a glance

Generic name	Noropin
Sponsor	The Hawkins Foundation
Modality	Small molecule
Therapeutic area	Other
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Comparison of Ropivacaine Alone Versus Combination of Dexamethasone and Clonidine for Block
Hip Scope Fascia-iliaca (FI) Block Study (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Noropin CI brief — competitive landscape report
Noropin updates RSS · CI watch RSS
The Hawkins Foundation portfolio CI